News and reporting on prostate cancer.
The insurer operates Blue Cross and Blue Shield plans in Illinois, Montana, New Mexico, Oklahoma, and Texas, and will now cover ConfirmMDx for its customers.
The positive insurance coverage decision for ConfirmMDx is one of several the company has received in recent months.
Biotechnology company SouthGenetics will distribute the prostate cancer test in countries including Argentina, Chile, Mexico, Peru, Panama, and Venezuela.
The positive coverage determination is one of several the company has received in recent months from various insurance companies for the ConfirmMDx test.
With the inclusion of ConfirmMDx in the Medi-Cal program, MDxHealth will seek access for the test in other state Medicaid programs.
Researchers from Northwestern University uncovered five circulating microRNAs that differentiate patients with very high- and low-risk prostate cancer.
The company credited the increased revenues to a 12 percent rise in the number of Oncotype Dx tests delivered.
The test uses the company's SIA platform, a protein biomarker technology that measures different protein isoform populations to assess patient disease states.
The findings may help identify which patients would be the best candidates for radiation therapy immediately following surgical removal of the prostate.